MX2021002302A - Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control. - Google Patents

Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control.

Info

Publication number
MX2021002302A
MX2021002302A MX2021002302A MX2021002302A MX2021002302A MX 2021002302 A MX2021002302 A MX 2021002302A MX 2021002302 A MX2021002302 A MX 2021002302A MX 2021002302 A MX2021002302 A MX 2021002302A MX 2021002302 A MX2021002302 A MX 2021002302A
Authority
MX
Mexico
Prior art keywords
ccr4
combination therapy
immune checkpoint
chemokine receptor
antagonists
Prior art date
Application number
MX2021002302A
Other languages
English (en)
Inventor
Venkat Reddy Mali
Ju Yang
Penglie Zhang
Rajinder Singh
Shijie Li
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2021002302A publication Critical patent/MX2021002302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción está dirigida a la terapia de combinación de un antagonista de Receptor de Quimiocina C-C 4 (CCR4) y uno o más inhibidores de punto de control inmune en el tratamiento del cáncer.
MX2021002302A 2018-08-29 2019-08-28 Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control. MX2021002302A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724412P 2018-08-29 2018-08-29
US201862771853P 2018-11-27 2018-11-27
PCT/US2019/048461 WO2020047030A1 (en) 2018-08-29 2019-08-28 Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Publications (1)

Publication Number Publication Date
MX2021002302A true MX2021002302A (es) 2021-04-28

Family

ID=69639506

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002302A MX2021002302A (es) 2018-08-29 2019-08-28 Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control.

Country Status (14)

Country Link
US (2) US11446289B2 (es)
EP (1) EP3843734A4 (es)
JP (1) JP2021536442A (es)
KR (1) KR20210053306A (es)
CN (1) CN112601526A (es)
AU (1) AU2019327430A1 (es)
BR (1) BR112021002928A2 (es)
CA (1) CA3109498A1 (es)
IL (1) IL280831B2 (es)
MA (1) MA53503A (es)
MX (1) MX2021002302A (es)
SG (1) SG11202101454PA (es)
TW (1) TW202023555A (es)
WO (1) WO2020047030A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103998429B (zh) 2011-12-01 2016-12-07 凯莫森特里克斯股份有限公司 作为ccr(4)拮抗剂的取代的苯胺类
EP3843734A4 (en) * 2018-08-29 2022-05-25 ChemoCentryx, Inc. COMBINATION THERAPY USING C-CHEMOCINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS
KR20230149729A (ko) * 2022-04-19 2023-10-27 케모센트릭스, 인크. Ccr4 길항제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
JP2007210887A (ja) 2004-06-21 2007-08-23 Astellas Pharma Inc 縮合二環性ピリミジン誘導体
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
EP2495263B1 (en) 2009-10-26 2014-04-16 China Petroleum & Chemical Corporation Supported non-metallocene catalyst, preparation method and uses thereof
US8952112B2 (en) 2009-10-26 2015-02-10 China Petroleum & Chemical Corp. Supported nonmetallocene catalyst, preparation and use thereof
US8541522B2 (en) 2009-10-28 2013-09-24 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
WO2011057469A1 (zh) 2009-11-13 2011-05-19 中国石油化工股份有限公司 负载型非茂金属催化剂、其制备方法及其应用
US8957169B2 (en) 2009-11-13 2015-02-17 China Petroleum & Chemical Corp. Supported nonmetallocene catalyst, preparation and use thereof
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
CN103998429B (zh) * 2011-12-01 2016-12-07 凯莫森特里克斯股份有限公司 作为ccr(4)拮抗剂的取代的苯胺类
WO2014163684A1 (en) * 2013-04-03 2014-10-09 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US11236139B2 (en) * 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
CN109803651B (zh) * 2016-06-27 2022-05-31 凯莫森特里克斯股份有限公司 免疫调节剂化合物
US10179787B2 (en) * 2016-07-29 2019-01-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018101448A1 (en) * 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
EP3843734A4 (en) * 2018-08-29 2022-05-25 ChemoCentryx, Inc. COMBINATION THERAPY USING C-CHEMOCINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE IMMUNE CHECKPOINT INHIBITORS

Also Published As

Publication number Publication date
JP2021536442A (ja) 2021-12-27
IL280831B1 (en) 2024-01-01
KR20210053306A (ko) 2021-05-11
EP3843734A1 (en) 2021-07-07
EP3843734A4 (en) 2022-05-25
CA3109498A1 (en) 2020-03-05
MA53503A (fr) 2021-07-07
WO2020047030A1 (en) 2020-03-05
US20230097128A1 (en) 2023-03-30
US20200069673A1 (en) 2020-03-05
BR112021002928A2 (pt) 2021-05-11
IL280831B2 (en) 2024-05-01
AU2019327430A1 (en) 2021-03-18
TW202023555A (zh) 2020-07-01
IL280831A (en) 2021-04-29
US11446289B2 (en) 2022-09-20
SG11202101454PA (en) 2021-03-30
CN112601526A (zh) 2021-04-02

Similar Documents

Publication Publication Date Title
MX2020003192A (es) Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1.
MX2021002302A (es) Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control.
MX2022000711A (es) Inhibidores de parp1.
MX2021013661A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos.
MX2020012137A (es) Inhibidores de mcl-1.
PH12020550936A1 (en) Combination drug including tlr7 agonist
NZ757213A (en) Compositions of plinabulin and use thereof
SG10201902137PA (en) Cenicriviroc combination therapy for the treatment of fibrosis
MX2018003179A (es) Terapia de combinación con cenicriviroc para el tratamiento de fibrosis.
MX2017005134A (es) Tratamiento del cáncer con inmunoestimuladores.
PH12018501903A1 (en) Methods of treating depression using orexin-2 receptor antagonists
MX2018009173A (es) Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash).
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR112018067938A2 (pt) combinação de um antagonista de cxcr4 e inibidor de ponto de verificação imunológica
TW201613577A (en) Pharmaceutical combinations
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
MX2023010063A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2021015628A (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
MX2021007391A (es) Regimenes de baja dosis extendida para inhibidores de mdm2.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2021013317A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.